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Mushroom poisonings occur when ingestion of wild mushrooms containing toxins takes place, placing
the consumers at life-threatening risk. In the present case report, an unusual multiple poisoning with
isoxazoles- and amatoxins-containing mushrooms in a context of altered mental state and poorly
controlled hypertension is presented. A 68-year-old female was presented to S~ao Jo~ao hospital (Portugal)
with complaints of extreme dizziness, hallucinations, vertigo and imbalance, 3 h after consuming a stew
of wild mushrooms. The ﬁrst observations revealed altered mental state and elevated blood pressure. The
examination of cooked mushroom fragments allowed a preliminary identiﬁcation of Amanita pantherina.
Gas chromatographyemass spectrometry (GCeMS) showed the presence of muscimol in urine. More-
over, through high-performance liquid chromatography-ultraviolet detection (HPLC-UV) analysis of the
gastric juice, the presence of a-amanitin was found, showing that amatoxins-containing mushrooms
were also included in the stew. After 4 days of supportive treatment, activated charcoal, silybin and N-
acetylcysteine, the patient recovered being discharged 10 days post-ingestion with no organ complica-
tions. The prompt and appropriate therapy protocol for life-threatening amatoxins toxicity probably
saved the patient's life as oral absorption was decreased and also supportive care was immediately
started.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
An altered mental state is a very common occurrence in the
emergency room and the diagnosis/treatment is highly challenging
(Xiao et al., 2012). In fact, two or more etiologies may coexist,
including pathological disorders, (e.g. hypoglycemia; cranialD, diode-array; EC, electro-
leic acid; GCeMS, gas chro-
ance liquid chromatography;
, total ion chromatogram; UV,
J. Garcia), felixdc@ff.up.pttrauma; alcohol; infection; psychoses; stroke; hypertensive,
metabolic, hepatic, or uremic encephalopathies), consumption of
psycho-active substances; and others (Schwartz et al., 1992).
Among these, possible accidental or intentional exposure to
psycho-active substances present in some wild mushroom species
should not be neglected (Tsujikawa et al., 2006). In fact, con-
sumption of wild mushrooms has increased substantially in the last
decades (Thimmel and Kluthe, 1998). Mushrooms are appreciated
worldwide as a delicacy, due to their exquisite palatability and
texture. Moreover, their chemical, nutritional, and functional
properties make them exceptional in the human diet (Cheung,
2010). The ingestion of wild mushrooms-containing toxins
frequently occurs, which can put the consumers at life-threatening
risk. Mushroom poisoning is usually accidental, rarely suicidal, and
frequently occurs as a result of misidentiﬁcation of a toxic
Fig. 1. Macroscopic identiﬁcation of Amanita pantherina found in the stew, showing its
characteristic features in a mushroom fragment (left). The cap fragments are brown
with whitish-brown warts (white arrow). (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
J. Garcia et al. / Toxicon 103 (2015) 55e5956mushroom as an edible species (Barbato, 1993; Cochran, 1987). The
severity of mushroom poisoning depends on the species of mush-
room, the amount of mushroom consumed, the prompt therapy
and the health status of the individual (Broussard et al., 2001;
Durukan et al., 2007). The main toxins associated to mushroom
poisoning are: cyclopeptides, orellanine, gyromitrin, isoxazoles,
muscarine, psilocybin and gastrointestinal speciﬁc irritants
(Koppel, 1993). Of the mentioned toxins, the most dangerous and
potentially fatal poisonings are caused by cyclopeptides (mainly
amatoxins) (Karlson-Stiber and Persson, 2003), while orellanine,
isoxazoles, muscarine, psilocybin, and gyromitrin can cause a
serious illness but are rarely fatal (Koppel, 1993). Amatoxins are
natural toxic bicyclic octapeptides present in mushroom species
from three different genera: Amanita, Galerina, and Lepiota (Vetter,
1998). The species Amanita phalloides is involved in the majority of
human fatal cases of mushroom poisoning (Karlson-Stiber and
Persson, 2003). Its main toxin is a-amanitin, which causes hepatic
and kidney damage, often fatal (Faulstich, 1979; Klein et al., 1989;
Santi et al., 2012). The mechanisms of toxicity of a-amanitin are
complex, but its most known mechanism is the inhibition of RNA
polymerase II (RNAP II) (Vetter, 1998).
Muscimol and ibotenic acid belong to the family of toxins
known as isoxazoles. Amanita pantherina and Amanita muscaria are
the most commonly known isoxazoles-containing mushrooms
(Diaz, 2005). Data on the incidence of intoxication by isoxazoles-
containing mushrooms are scarce. The severity of the symptoms
ismild, thus intoxicated people often do not seekmedical attention.
In Portugal, very few cases of isoxazoles-containing mushrooms
intoxications have been reported (Morgado et al., 2006). The
American Association of Poison Control Centers annual report of
2012 presented 36 cases of isoxazoles-containing mushroom in-
toxications in the United States of America, with no related deaths
(Mowry et al., 2013). Ibotenic acid is an agonist of glutamic acid
receptors; its decarboxylated derivative, muscimol, is an agonist of
gamma-aminobutyric acid (GABA) receptors. The central effects of
these toxins are generally attributed to the previously mentioned
pharmacological properties (Krogsgaard-Larsen et al., 1980;
Michelot and Melendez-Howell, 2003; Snodgrass, 1978) and
include hallucinations, confusion, dizziness, visual and auditory
aesthesia (hypersensitivity), space distortion, and unawareness of
time (Michelot and Melendez-Howell, 2003).
In this work, we describe a case of a 68-years-old patient with
poorly controlled hypertension and altered mental state after
eating wild mushrooms, and the respective clinical management of
the patient. The suspicion of a hypertensive crisis and isoxazoles-
and amatoxins-containing mushrooms poisoning were taken into
consideration in the medical decisions.
2. Case report
A 68-years-old female with hypertension was admitted to the
emergency room of S~ao Jo~ao Hospital (Porto, Portugal) after
ingestion of mushrooms. After speciﬁc query, her son reported that
the patient ingested several wild mushrooms that were collected in
a public yard by the patient. She stewed the mushrooms, and,
immediately after ingestion, she started experiencing dizziness,
vertigo and imbalance. She self-induced vomiting and had no
symptoms of nausea, spontaneous vomiting or diarrhea. On
admission, 3 h post-ingestion, the examination revealed an altered
mental status including confusion and repetitive speech, only
responsive to severe painful stimuli, and mydriatic pupils. These
symptoms resolved in a few hours after admission. Initial emer-
gency room vital signs were: blood pressure 230/108 mmHg,
normal pulse and respiratory rate, temperature 96.8 F, and oxygen
saturation of 97.5 percent using an oxygen mask at 10 L/min.Physical examination demonstrated dry skin and dry mucous
membranes. Additionally, she had clear breath and heart sounds,
no abdominal tenderness, and no gross focal neurologic deﬁcits. A
brain computed tomographywas immediately performed revealing
no abnormalities. Additionally, electrocardiogram, funduscopy and
urinary sediment were analyzed demonstrating no evidence of
lesions. Her serial hematological parameters, coagulation proﬁle,
liver and renal function tests were normal.
As a standard procedure for intoxications with wild mushrooms
and until species identiﬁcation by the laboratory, the general
detoxiﬁcation treatment with oral-activated charcoal was imme-
diately instituted on admission, and followed the speciﬁc treatment
forA. phalloidespoisoning, through the administration of silybin and
N-acetylcysteine. N-acetylcysteine and silybinwere administered in
a loading dose of 10.5 g (150 mg/kg) and 350 mg (5 mg/kg),
respectively, followed by perfusion. The perfusion of silybin was
maintained at a dosage of 58 mg/h (20 mg/kg/d) and N-acetylcys-
teine at 875 mg/h (12.5 mg/kg/h) for the following 4 h. Labetalol
perfusion was also administered for blood pressure control. The
patient was then transferred to the intermediate care unit to
continuewith the treatmentwith continuous surveillance. A total of
300 mg/kg of N-acetylcysteine was administered in the ﬁrst 21 h
after admission. The perfusion of activated charcoal and silybinwas
kept until the fourth day (at the fourth day, normal coagulation
proﬁle and liver function tests were observed). Serum aminotrans-
ferases and coagulation proﬁle were normal during all the time that
the patient remained admitted, although an elevation of total bili-
rubin (twofold the normal value) was observed at day 2 (conjugated
bilirubin was normal at that time). Two days, total bilirubin level
started todecline, and it normalizedwithinoneweek. After labetalol
perfusion, the blood pressure control was achieved by administra-
tion of sublingual captopril until the fourth day.
The patient kept some of the stew's leftovers, which were then
provided for analysis. The identiﬁcation of the mushrooms was
ﬁrstly performed by 2 experts based on the macroscopic features of
the fruiting body (Courtecuisse, 1999; Courtecuisse and Duhem,
2005). In the stewed mushrooms, the color of some of the cap
fragments resembled A. pantherina, namely brown with whitish-
brown warts (Fig. 1). The gills were free and whitish-brown color
and the stipe was cylindrical and seemed to be white. Therefore, to
conﬁrm the intoxication by A. pantherina, we looked for the
Fig. 3. Chromatogram of the patient's gastric juice recorded at 305 nm superposed to
the chromatograms of the same sample spiked with a-amanitin and standard solution
of 20 mg/mL of a-amanitin.
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method of derivatization with N-methyl-N-(trimethylsilyl)triﬂuor-
oacetamide (MSTFA) reported in Carvalho et al. 2014. Gas chro-
matographyemass spectrometry (GCeMS) analysis conﬁrmed the
presence of muscimol (Fig. 2) in the patient's urine. The data
allowed to identify the putative responsible for the patient's
hallucinogenic effects, since she possibly ingested ibotenic acid and
muscimol-containing mushrooms. Since the possibility of an
A. phalloides intoxication is extremely severe, the presence of the
main toxin of this mushroom was investigated in the biological
ﬂuids (urine and gastric juice) and in the mushrooms collected. a-
Amanitin was identiﬁed in the gastric ﬂuid by high-performance
liquid chromatography with ultraviolet detection (Fig. 3), as pre-
viously described (Garcia et al., 2014). The a-amanitin levels in the
gastric ﬂuid were 1.12 mg/mL, whereas no detectable levels of a-
amanitin were found in the urine [the method limit of detection is
0.05 mg/mL (Garcia et al., 2014)].
In the ﬁfth day after mushroom ingestion, the patient was dis-
charged from the intermediate care and transferred to the wardFig. 2. Zoomed views for the part of GCeMS total ion chromatograms corresponding to the muscimol peak after the derivatization. A) muscimol standard, B) blank urine, and C)
patient's urine. Mass spectrum of D) derivatized muscimol standard and E) patient's urine. The molecular ion m/z 331 and chemical formula of derivatized muscimol are
represented.
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pressure control. Ten days post-ingestion the patient was dis-
charged home with no organ complications.
3. Discussion
Altered mental status comprises clinical symptoms including
cognitive disorders, attention disorders, arousal disorders, and
decreased level of consciousness (Xiao et al., 2012). It is a very
common situation in the emergency room, and it hasmany possible
causes, including pathological disorders and as a result of con-
sumption of psycho-actives substances (Xiao et al., 2012). In the
case presented herein, the high blood pressure in association with
altered mental status lead to suspicion of a hypertensive crisis case.
However, the clinical evaluation showed no lesion in target organs
(normal brain computed tomography, electrocardiogram, fundu-
scopy and urinary sediment), thus that hypothesis was discarded.
At the same time, the history of wild mushroom consumption
resulted in clinical preventive measures to counteract its putative
life-threatening toxicity. Worldwide, most cases of intoxications by
wild mushrooms have been attributed to amatoxin-containing
mushrooms (Brand~ao et al., 2011; Mowry et al., 2013), with only a
very small percentage of cases attributed to ibotenic acid and
muscimol-containing mushrooms (Morgado et al., 2006; Mowry
et al., 2013).
In the case presented herein, the features of the clinical pre-
sentation are consistent with the diagnosis of intoxication by
isoxazoles-containing mushrooms. Positive identiﬁcation of
A. pantherina mushroom, found in the patient's home, was
accomplished by 2 experts. This species contains the toxins ibotenic
acid and muscimol (Michelot and Melendez-Howell, 2003). Ibo-
tenic acid is metabolized to muscimol (Michelot and Melendez-
Howell, 2003) and the presence of muscimol was conﬁrmed in
the patient's urine sample. Muscimol and ibotenic acid cross the
bloodebrain barrier exerting their effects primarily on the Central
Nervous System (CNS), where they act as neurotransmitter agonists
(Michelot and Melendez-Howell, 2003). Ibotenic acid mimics the
excitatory amino acid glutamic acid and acts on N-methyl-D-
aspartic acid (NMDA) receptors. Muscimol is a potent agonist of
GABAA receptors and also exerts CNS effects (Michelot and
Melendez-Howell, 2003). Nausea, hallucinations, delirium, and
sleepiness are often described after isoxazoles-containing mush-
rooms ingestion (Diaz, 2005; Satora et al., 2006). The toxic
threshold estimated for ibotenic acid and muscimol is 30e60 mg
and 6 mg, respectively (Halpern, 2004) and these amounts can be
found in a single mushroom (Rumack and Spoerke, 1994). At this
point, the toxicokinetics of either muscimol or ibotenic acid re-
mains largely unknown, but based on the rapid onset of symptoms
after mushrooms ingestion, a fast absorption of toxins is presumed.
Moreover, the toxins are readily excreted in urine, where they can
be detected within 1 h after ingestion (Stribrny et al., 2012). Clinical
symptoms have been reported 30 min to 2 h after ingestion and
include nausea, hallucinations, delirium, muscular spasm, and
sleepiness (Diaz, 2005; Satora et al., 2006). The CNS effects are
usually short-lived, and fatalities rarely occur (Benjamin, 1992;
Diaz, 2005), thus the recommended treatment for isoxazoles-
containing mushrooms consists of eliminating the toxins from
the gastrointestinal tract, administration of activated charcoal, and
supportive measures to alleviate CNS symptoms (Michelot and
Melendez-Howell, 2003). Even when the intoxication symptoms
largely indicate a self-limited mushroom intoxication, if the pa-
tient's meal contained wild mushrooms, the possible presence of
amatoxins should not be ruled out and should be taken into
consideration in the medical protocol. Amatoxins are a group of
toxic bicyclic octapeptides present in the genus Amanita. a-Amanitin is considered the main responsible for the human toxic
effects. Upon ingestion, a-amanitin binds to the RNAP II enzyme,
inhibits the transcription process and, ultimately, causes cell death.
The main target organ seems to be the liver (Letschert et al., 2006)
but the kidneys can also be compromised (Amini et al., 2011). In the
liver, a-amanitin causes broad necrosis that results in acute hepatic
failure and further complications, such as hepatic coma, coagula-
tion disorders, renal failure (Enjalbert et al., 2002). The estimated
lethal dose of amatoxins in humans is about 0.1mg/kg bodyweight,
or even lower, and this lethal amount may be present in a single
mushroom (Faulstich, 1980). Upon ingestion, amatoxins seem to be
gradually absorbed in the gastrointestinal tract. In the present case,
the patient was taken to the hospital emergency room 3 h after
mushrooms ingestion and the presence of a-amanitin was
conﬁrmed in the gastric juice but not in the urine sample taken. We
can presume that the fast CNS symptoms elicited the fast hospital
admission, even before the amatoxins were fully absorbed. The
gastric lavage was immediately performed in the hospital and
decreased or even abrogated the absorption of the toxins. The
clinical course after amatoxins intoxication is initially characterized
by a latent period followed by gastrointestinal symptoms, which
include nausea, diarrhea and vomiting. However, no amatoxins
toxicity signs or symptoms are usually found until 6e24 h after
ingestion (Enjalbert et al., 2002). Presently, there is currently no
speciﬁc and effective antidote for A. phalloides poisoning but
several therapeutic drugs are used to protect the target organs of
amatoxins poisoning. Intravenous silybin is the pharmacologic
treatment of choice in Europe (Mengs et al., 2012) and in the USA
(French et al., 2011). Other therapies have been suggested and
include benzylpenicillin, ceftazidime, or N-acetylcysteine
(Enjalbert et al., 2002). The administration of silybin in amatoxin
poisoning cases is based on its strong antioxidant activity and the
ability to stimulate RNA polymerase I, counterbalancing the inhi-
bition of RNAP II activity caused by amatoxins (Fraschini et al.,
2002). N-acetylcysteine's potential therapeutic effect is due to its
known antioxidant activity (Montanini et al., 1999).
Since a-amanitin undergoes extensive enterohepatic recycling,
repeated doses of activated charcoal were, also, administered, to
enhance its elimination. The administration of activated charcoal
had implications in the choice of the administration route of the
antihypertensive drug to be used. Activated charcoal may prevent
the absorption of orally administered therapeutic agents; therefore
sublingual captopril was administered.
In summary, in the present case, the treatment of a patient that
suffered mushroom intoxication was immediately started after
patient's admission and consisted of gastric lavage, oral-activated
charcoal, silybin and N-acetylcysteine, and antihypertensive ther-
apy. It can be inferred that the early hospitalization, rapid diagnosis
and aggressive management concurred for the successful outcome
after A. phalloides lethal mushroom poisoning. Every effort should
be made to identify the toxins present in the mushrooms ingested
as to continuewith supportive therapy or not, but clinical measures
should not wait for the analytical results, as time is of the essence in
these cases. In the present situation, the simultaneous ingestion of
isoxazoles toxins and amatoxins lead to the early application of the
A. phalloides therapy protocol in hospital settings, since the former
caused rapid hallucinogenic symptoms. The facilities for toxico-
logical analysis are not commonly available in most hospitals. The
collaboration between hospitals and toxicological laboratories and
the communication between physicians and toxicologists could be
helpful in reducing the time of therapy implemented, as well as the
morbidity and mortality in cases of poisoning. The rapid hospital-
ization and the history of mushrooms ingestion led to an early
therapeutic intervention in an amatoxins poisoning, which was key
to prevent complications resulting from amatoxins intoxication.
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